- Home
- PNI vs ANVS Comparison
PNI vs ANVS Comparison
Compare PNI & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | ANVS |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 76.6M |
| IPO Year | 2002 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PNI | ANVS |
|---|---|---|
| Price | $6.53 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 77.3K | ★ 997.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.64 | $1.22 |
| 52 Week High | $7.20 | $5.50 |
Technical Indicators
Market Signals| Indicator | PNI | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 17.19 | 22.48 |
| Support Level | N/A | N/A |
| Resistance Level | $7.07 | $2.02 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 3.57 | 3.65 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.